Advanced search
Publication Cover
Leukemia & Lymphoma Volume 50, 2009 - Issue 6
Submit an article Journal homepage
1,875
Views
87
CrossRef citations to date
0
Altmetric
Reviews

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab

Dirk Nagorsen Micromet AG, Staffelseestr. 2, 81477 Munich, GermanyCorrespondence[email protected]
,
Ralf Bargou Department of Hematology and Oncology and Phase I Unit of the Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Klinikstraße 6-8, 97070 Würzburg, Germany
,
Dominik Rüttinger Micromet AG, Staffelseestr. 2, 81477 Munich, Germany
,
Peter Kufer Micromet AG, Staffelseestr. 2, 81477 Munich, Germany
,
Patrick A. Baeuerle Micromet AG, Staffelseestr. 2, 81477 Munich, Germany
&
Gerhard Zugmaier Micromet AG, Staffelseestr. 2, 81477 Munich, Germany
Pages 886-891 | Received 20 Jan 2009, Accepted 01 Apr 2009, Published online: 21 Jul 2009

Citations (87)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (17)

Meixiao Long, Alice S. Mims & Zihai Li. (2022) Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement. Immunological Investigations 51:8, pages 2176-2214.
Read now
Luca Bertamini, Francesca Bonello, Mario Boccadoro & Sara Bringhen. (2020) New drugs in early development for treating multiple myeloma: all that glitters is not gold. Expert Opinion on Investigational Drugs 29:9, pages 989-1004.
Read now
Richard Burt, Dana Warcel & Adele K. Fielding. (2019) Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. Human Vaccines & Immunotherapeutics 15:3, pages 594-602.
Read now
Thomas Van Blarcom, Kevin Lindquist, Zea Melton, Wai Ling Cheung, Chris Wagstrom, Dan McDonough, Cendy Valle Oseguera, Sheng Ding, Andrea Rossi, Shobha Potluri, Purnima Sundar, Steven Pitts, Marina Sirota, Meri Galindo Casas, Yu Yan, Jeffrey Jones, Zygy Roe-Zurz, Surabhi Srivatsa Srinivasan, Wenwu Zhai, Jaume Pons, Arvind Rajpal & Javier Chaparro-Riggers. (2018) Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies. mAbs 10:2, pages 256-268.
Read now
Manon Queudeville, Rupert Handgretinger & Martin Ebinger. (2017) Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab. OncoTargets and Therapy 10, pages 3567-3578.
Read now
Shiyong Gong, Fang Ren, Danqing Wu, Xuan Wu & Chengbin Wu. (2017) Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets. mAbs 9:7, pages 1118-1128.
Read now
Sheilagh Sanders & Douglas A. Stewart. (2017) Targeting non-Hodgkin lymphoma with blinatumomab. Expert Opinion on Biological Therapy 17:8, pages 1013-1017.
Read now
Maria-Elisabeth Goebeler & Ralf Bargou. (2016) Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leukemia & Lymphoma 57:5, pages 1021-1032.
Read now
Archana Thakur & Lawrence G. Lum. (2016) “NextGen” Biologics: Bispecific Antibodies and Emerging Clinical Results. Expert Opinion on Biological Therapy 16:5, pages 675-688.
Read now
Yangyang Wang, Claudia Geldres, Soldano Ferrone & Gianpietro Dotti. (2015) Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors. Expert Opinion on Therapeutic Targets 19:10, pages 1339-1350.
Read now
Pawel Robak, Piotr Smolewski & Tadeusz Robak. (2015) Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opinion on Emerging Drugs 20:3, pages 423-447.
Read now
Britny Rogala, Craig W Freyer, Evelena P Ontiveros, Elizabeth A Griffiths, Eunice S Wang & Meir Wetzler. (2015) Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies. Expert Opinion on Biological Therapy 15:6, pages 895-908.
Read now
Nadine Kutsch, Michael Hallek & Barbara Eichhorst. (2015) Emerging therapies for refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 56:2, pages 285-292.
Read now
Craig A. Portell & Anjali S. Advani. (2014) Novel targeted therapies in acute lymphoblastic leukemia. Leukemia & Lymphoma 55:4, pages 737-748.
Read now
Pier Paolo Piccaluga, Mario Arpinati, Anna Candoni, Claudio Laterza, Stefania Paolini, Anna Gazzola, Elena Sabattini, Giuseppe Visani & Stefano A. Pileri. (2011) Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leukemia & Lymphoma 52:2, pages 325-327.
Read now
Andrew J Leishman, Gary P Sims, Matthew Sleeman & Martin Braddock. (2011) Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity. Expert Opinion on Investigational Drugs 20:1, pages 23-39.
Read now
Jijie Gu & Tariq Ghayur. (2010) Rationale and development of multispecific antibody drugs. Expert Review of Clinical Pharmacology 3:4, pages 491-508.
Read now

Articles from other publishers (70)

Vita Golubovskaya. (2023) Editorial on “Cell Therapy, Bispecific Antibodies and Other Immunotherapies against Cancer”. Cancers 15:20, pages 5053.
Crossref
Andreas A. Hombach, Christine Ambrose, Roy Lobb, Paul Rennert & Hinrich Abken. (2023) A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2+ Solid Cancer. Cells 12:2, pages 248.
Crossref
Pauline Mocquot, Yasmine Mossazadeh, Léopoldine Lapierre, Fanny Pineau & Fabien Despas. (2022) The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials. Journal of Clinical Pharmacy and Therapeutics 47:9, pages 1337-1351.
Crossref
Dain Moon, Nara Tae, Yunji Park, Seung-Woo Lee & Dae Hee Kim. (2022) Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody. Immune Network 22:1.
Crossref
John C. Molina & Nirali N. Shah. 2022. Clinical Management of Acute Lymphoblastic Leukemia. Clinical Management of Acute Lymphoblastic Leukemia 295 328 .
Elisavet Vlachonikola, Kostas Stamatopoulos & Anastasia Chatzidimitriou. (2021) T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia. Cancers 13:13, pages 3255.
Crossref
Melissa C. Mackey, Serena Chew, Hagop M. Kantarjian & Elias Jabbour. 2021. Acute Leukemias. Acute Leukemias 169 184 .
Maria-Elisabeth Goebeler & Ralf C. Bargou. (2020) T cell-engaging therapies — BiTEs and beyond. Nature Reviews Clinical Oncology 17:7, pages 418-434.
Crossref
C. Grüllich, E. Nößner, D. Pfister & V. Grünwald. (2020) Molekulare zielgerichtete Therapie und Immuntherapie des ProstatakarzinomsTargeted molecular therapy and immunotherapy for prostate cancer. Der Urologe 59:6, pages 687-694.
Crossref
Shinji YamadaMika K. KanekoYusuke SayamaTeizo AsanoMasato SanoMiyuki YanakaTakuro NakamuraSaki OkamotoSaori HandaYu KomatsuYoshimi NakamuraYoshikazu FurusawaJunko TakeiYukinari Kato. (2020) Development of Novel Mouse Monoclonal Antibodies Against Human CD19. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 39:2, pages 45-50.
Crossref
Joana H. Ministro, Soraia S. Oliveira, Joana G. Oliveira, Miguel Cardoso, Frederico Aires-da-Silva, Sofia Corte-Real & Joao Goncalves. (2020) Synthetic antibody discovery against native antigens by CRISPR/Cas9-library generation and endoplasmic reticulum screening. Applied Microbiology and Biotechnology 104:6, pages 2501-2512.
Crossref
Shipra Gandhi, Aman Gupta, Pankit Vachhani,Igor Puzanov & Marc S. Ernstoff. 2020. Handbook of Cancer Treatment-Related Symptons and Toxicities. Handbook of Cancer Treatment-Related Symptons and Toxicities 259 276 .
Nicola Gökbuget. 2020. Current Immunotherapeutic Strategies in Cancer. Current Immunotherapeutic Strategies in Cancer 71 91 .
Alan Herbert. (2019) Contextual Cell Death in Adaptive Immunity: Selecting a Winning Response. Frontiers in Immunology 10.
Crossref
Jeff P. Sharman. (2019) Targeting CD20: teaching an old dog new tricks. Hematology 2019:1, pages 273-278.
Crossref
Anjali S. Advani & Edward A. Copelan. (2019) Navigating the nexus of MRD and novel agents in ALL. Hematology 2019:1, pages 9-16.
Crossref
Shilpa Paul, Caitlin R. Rausch, Mary Alma Welch, Hagop M. Kantarjian & Elias J. Jabbour. (2019) SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia 19:8, pages 471-479.
Crossref
Honghui Zhou & Diane R. MouldPradeep B. Lukka, Santosh Wagh & Bernd Meibohm. 2019. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune‐Mediated Inflammatory Diseases. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune‐Mediated Inflammatory Diseases 187 208 .
Grace Egan, Sheila Weitzman & Sarah Alexander. 2019. Non-Hodgkin's Lymphoma in Childhood and Adolescence. Non-Hodgkin's Lymphoma in Childhood and Adolescence 167 183 .
Joana Ministro, Ana Margarida Manuel & Joao Goncalves. 2020. Current Applications of Pharmaceutical Biotechnology. Current Applications of Pharmaceutical Biotechnology 55 86 .
Limin Lin, Li Li, Changhua Zhou, Jing Li, Jiayu Liu, Rui Shu, Bin Dong, Qing Li & Zhong Wang. (2018) A HER2 bispecific antibody can be efficiently expressed in Escherichia�coli with potent cytotoxicity. Oncology Letters.
Crossref
Troy Z. Horvat, Amanda N. Seddon, Adebayo Ogunniyi, Amber C. King, Larry W. Buie & Ryan J. Daley. (2017) The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia. Annals of Pharmacotherapy 52:3, pages 268-276.
Crossref
David MerriamConnie ChenGema Méndez-LagaresKenneth A. RogersAnthony J. MichaelsJiangli YanPaul CasazKeith A. ReimannFrançois VillingerDennis J. Hartigan-O'Connor. (2017) Depletion of Gut-Resident CCR5 + Cells for HIV Cure Strategies . AIDS Research and Human Retroviruses 33:S1, pages S-70-S-80.
Crossref
Christiane Chen-Santel. 2017. Childhood Acute Lymphoblastic Leukemia. Childhood Acute Lymphoblastic Leukemia 201 237 .
Judith Feucht, Simone Kayser, David Gorodezki, Mohamad Hamieh, Michaela Döring, Franziska Blaeschke, Patrick Schlegel, Hans Bösmüller, Leticia Quintanilla-Fend, Martin Ebinger, Peter Lang, Rupert Handgretinger & Tobias Feuchtinger. (2016) T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget 7:47, pages 76902-76919.
Crossref
Min Zhu, Benjamin Wu, Christian Brandl, Jessica Johnson, Andreas Wolf, Andrew Chow & Sameer Doshi. (2016) Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. Clinical Pharmacokinetics 55:10, pages 1271-1288.
Crossref
Andreas Baumann, Stephanie Fischmann, Guenter Blaich & Matthias Friedrich. (2016) Leverage nonclinical development of bispecifics by translational science. Drug Discovery Today: Technologies 21-22, pages 95-102.
Crossref
Marina Bacac, Tanja Fauti, Johannes Sam, Sara Colombetti, Tina Weinzierl, Djamila Ouaret, Walter Bodmer, Steffi Lehmann, Thomas Hofer, Ralf J. Hosse, Ekkehard Moessner, Oliver Ast, Peter Bruenker, Sandra Grau-Richards, Teilo Schaller, Annette Seidl, Christian Gerdes, Mario Perro, Valeria Nicolini, Nathalie Steinhoff, Sherri Dudal, Sebastian Neumann, Thomas von Hirschheydt, Christiane Jaeger, Jose Saro, Vaios Karanikas, Christian Klein & Pablo Umaña. (2016) A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors. Clinical Cancer Research 22:13, pages 3286-3297.
Crossref
Matthew J. Barth, Yaya Chu, Patrick J. Hanley & Mitchell S. Cairo. (2016) Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. British Journal of Haematology 173:4, pages 597-616.
Crossref
Shintaro Taki, Haruhiko Kamada, Masaki Inoue, Kazuya Nagano, Yohei Mukai, Kazuma Higashisaka, Yasuo Yoshioka, Yasuo Tsutsumi & Shin-ichi Tsunoda. (2015) A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy. PLOS ONE 10:12, pages e0144712.
Crossref
Jingjing Wu, Jiaping Fu, Mingzhi Zhang & Delong Liu. (2015) Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. Journal of Hematology & Oncology 8:1.
Crossref
D. J. DeAngelo. (2015) The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia. Hematology 2015:1, pages 400-405.
Crossref
Sonali M. Smith & Julie M. Vose. 2015. Targeted Therapy in Translational Cancer Research. Targeted Therapy in Translational Cancer Research 169 176 .
Larry W. Buie, Joshua J. Pecoraro, Troy Z. Horvat & Ryan J. Daley. (2015) Blinatumomab. Annals of Pharmacotherapy 49:9, pages 1057-1067.
Crossref
Leonard Sender & Keri B. Zabokrtsky. (2015) Adolescent and young adult patients with cancer: a milieu of unique features. Nature Reviews Clinical Oncology 12:8, pages 465-480.
Crossref
George J. Weiner. (2015) Building better monoclonal antibody-based therapeutics. Nature Reviews Cancer 15:6, pages 361-370.
Crossref
Gillian A Horne, Ross Kinstrie & Mhairi Copland. (2015) Novel drug therapies in myeloid leukemia: a patent review. Pharmaceutical Patent Analyst 4:3, pages 187-205.
Crossref
Jianxuan Zou, Dan Chen, Yunhui Zong, Sisi Ye, Jinle Tang, Huimin Meng, Gangli An, Xingding Zhang & Lin Yang. (2015) Immunotherapy based on bispecific T‐cell engager with hIgG 1 Fc sequence as a new therapeutic strategy in multiple myeloma . Cancer Science 106:5, pages 512-521.
Crossref
Jing Ai & Anjali Advani. (2015) Current status of antibody therapy in ALL. British Journal of Haematology 168:4, pages 471-480.
Crossref
Jon E. Arnason & Jennifer R. Brown. (2015) Targeted Therapy for Chronic Lymphocytic Leukemia: Current Status and Future Directions. Drugs 75:2, pages 143-155.
Crossref
Ignazio Caruana, Iulia Diaconu & Gianpietro Dotti. (2014) From Monoclonal Antibodies to Chimeric Antigen Receptors for the Treatment of Human Malignancies. Seminars in Oncology 41:5, pages 661-666.
Crossref
Matthias Friedrich, Anja Henn, Tobias Raum, Monika Bajtus, Katja Matthes, Larissa Hendrich, Joachim Wahl, Patrick Hoffmann, Roman Kischel, Majk Kvesic, Jerry W. Slootstra, Patrick A. Baeuerle, Peter Kufer & Benno Rattel. (2014) Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia. Molecular Cancer Therapeutics 13:6, pages 1549-1557.
Crossref
Feng Yu, Xingbing Wang, Z Sheng Guo, David L Bartlett, Stephen M Gottschalk & Xiao-Tong Song. (2014) T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy. Molecular Therapy 22:1, pages 102-111.
Crossref
Michael Hallek. (2013) Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. American Journal of Hematology 88:9, pages 803-816.
Crossref
Emmet McCormack, Katherine J. Adams, Namir J. Hassan, Akhil Kotian, Nikolai M. Lissin, Malkit Sami, Maja Muji?Tereza Osdal, Bj?rn Tore Gjertsen, Deborah Baker, Alex S. Powlesland, Milos Aleksic, Annelise Vuidepot, Olivier Morteau, Deborah H. Sutton, Carl H. June, Michael Kalos, Rebecca Ashfield & Bent K. Jakobsen. (2012) Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunology, Immunotherapy 62:4, pages 773-785.
Crossref
Nikolai M. Lissin, Namir J. Hassan & Bent K. Jakobsen. 2013. Fusion Protein Technologies for Biopharmaceuticals. Fusion Protein Technologies for Biopharmaceuticals 495 505 .
Tadeusz Robak. (2013) Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. Future Oncology 9:1, pages 69-91.
Crossref
Katayoun Rezvani, Joshua D. Brody, Holbrook E. Kohrt, Aaron C. Logan, Ranjana Advani, Debra Katherine Czerwinski, Wen-Kai Weng, Robert S. Negrin, Victoria Carlton, Malek Faham, Ronald Levy & John Barrett. (2013) Cancer Vaccines and T Cell Therapy. Biology of Blood and Marrow Transplantation 19:1, pages S97-S101.
Crossref
Monali Vasekar, Joshua E. Allen, Jamal Joudeh & David Claxton. 2013. Impact of Genetic Targets on Cancer Therapy. Impact of Genetic Targets on Cancer Therapy 341 358 .
Tadeusz Robak. 2013. Non-Hodgkin Lymphoma. Non-Hodgkin Lymphoma 191 212 .
Dirk Nagorsen, Peter Kufer, Patrick A. Baeuerle & Ralf Bargou. (2012) Blinatumomab: A historical perspective. Pharmacology & Therapeutics 136:3, pages 334-342.
Crossref
S.-R. Kuo, L. Wong & J.-S. Liu. (2012) Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Protein Engineering Design and Selection 25:10, pages 561-570.
Crossref
Lisa M. Pörtner, Kathrin Schönberg, Maryam Hejazi, Daniela Brünnert, Frank Neumann, Lars Galonska, Uwe Reusch, Melvyn Little, Rainer Haas & Markus Uhrberg. (2012) T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16. Cancer Immunology, Immunotherapy 61:10, pages 1869-1875.
Crossref
Fabrice Le Gall, Uwe Reusch, Anastasia Y. Bakulina & Sergej M. Kiprijanov. (2012) WITHDRAWN: Tetravalent Bispecific Single-Chain Fv Antibodies for Lysis of Leukemia Cells by Autologous T Cells. Journal of Molecular Biology.
Crossref
Craig A. Portell & Anjali S. Advani. (2012) Antibody Therapy for Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports 7:2, pages 153-159.
Crossref
Uli Binder & Arne Skerra. 2012. Therapeutic Proteins. Therapeutic Proteins 63 80 .
Kevin S. Chen & Duane A. Mitchell. 2012. Glioma. Glioma 121 141 .
Suzanne L. TopalianGeorge J. WeinerDrew M. Pardoll. (2011) Cancer Immunotherapy Comes of Age. Journal of Clinical Oncology 29:36, pages 4828-4836.
Crossref
Mark R. Litzow. (2011) Novel Therapeutic Approaches for Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America 25:6, pages 1303-1317.
Crossref
Sergej M. Kiprijanov. 2011. Drug Delivery in Oncology. Drug Delivery in Oncology 441 482 .
David Wong & Shan Jameson. 2011. Chemistry of Protein and Nucleic Acid Cross-Linking and Conjugation, Second Edition. Chemistry of Protein and Nucleic Acid Cross-Linking and Conjugation, Second Edition 191 238 .
Lyudmyla Derby & Myron S Czuczman. (2011) Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders. Future Oncology 7:8, pages 963-979.
Crossref
Carlos Graux. (2011) Biology of acute lymphoblastic leukemia (ALL): Clinical and therapeutic relevance. Transfusion and Apheresis Science 44:2, pages 183-189.
Crossref
Dafne Müller & Roland E. Kontermann. 2011. Antibody Expression and Production. Antibody Expression and Production 235 249 .
Patrick A. Baeuerle, Gerhard Zugmaier & Dominik Rüttinger. 2011. Bispecific Antibodies. Bispecific Antibodies 273 287 .
Alisa B. Lee‐Sherick, Rachel M. A. Linger, Lia Gore, Amy K. Keating & Douglas K. Graham. (2010) Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. British Journal of Haematology 151:4, pages 295-311.
Crossref
Sophie Dupire & Bertrand Coiffier. (2010) Targeted treatment and new agents in diffuse large B cell lymphoma. International Journal of Hematology 92:1, pages 12-24.
Crossref
Kenneth P. Micklethwaite, Barbara SavoldoPatrick J. Hanley, Ann M. LeenGail J. Demmler-HarrisonLaurence J. N. Cooper, Hao Liu, Adrian P. GeeElizabeth J. Shpall, Cliona M. RooneyHelen E. Heslop, Malcolm K. Brenner, Catherine M. Bollard & Gianpietro Dotti. (2010) Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood 115:13, pages 2695-2703.
Crossref
Christoph Stein, Christian Kellner, Markus Kügler, Nina Reiff, Kristin Mentz, Michael Schwenkert, Bernhard Stockmeyer, Andreas Mackensen & Georg H. Fey. (2010) Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. British Journal of Haematology 148:6, pages 879-889.
Crossref
Helma Freitag, Gesine Gress, Kim Messer, Gülcan Sivaz, Olga Weinbender, Ilse Zündorf & Theo Dingermann. (2009) Bitte ein BiTE ® ! . Pharmazie in unserer Zeit 38:5, pages 396-398.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.